Summary:
In adults with chronic kidney disease (eGFR ≥25, UACR 30-3,500 mg/g) and overweight/obesity (BMI ≥27) without diabetes, semaglutide 2.4 mg subcutaneous injection weekly for 24 weeks reduced UACR by 52.1% (95% CI -65.5% to -33.4%, P<0.0001) compared to matching placebo injection weekly, with GI adverse events more common but consistent with known GLP-1 RA safety profile.
| PICO | Description |
|---|---|
| Population | Adults with CKD (eGFR ≥25, UACR 30-3,500) and BMI ≥27 without diabetes. |
| Intervention | Semaglutide 2.4 mg subcutaneous weekly for 24 weeks, titrated per protocol. |
| Comparison | Matching placebo injection weekly for 24 weeks. |
| Outcome | UACR reduced 52.1% vs placebo. GI adverse events as expected with GLP-1 RAs. |
Clinical Context
CKD affects ~700 million worldwide. Obesity drives CKD progression through glomerular hyperfiltration and inflammation. Albuminuria is an independent risk factor for CKD progression.
Clinical Pearls
1. Glucose-Independent Kidney Protection: Benefits aren’t mediated solely through glucose lowering.
2. Magnitude of Albuminuria Reduction: 52% UACR reduction is comparable to ACE inhibitors or ARBs.
3. Extending Beyond Diabetes: Expands evidence base to non-diabetic CKD with obesity.
4. Weight Loss Contribution: Both weight loss and potential direct renal effects contribute.
Practical Application
Consider semaglutide for patients with CKD and obesity without diabetes, particularly those with significant albuminuria. Complements RAS blockade and SGLT2 inhibitors.
Study Limitations
Short duration (24 weeks) with surrogate endpoint. Hard kidney outcomes require longer follow-up.
Bottom Line
Semaglutide 2.4 mg weekly reduces albuminuria by 52% in non-diabetic adults with CKD and obesity—a glucose-independent kidney benefit.
Source: Apperloo EM, et al. “Semaglutide in Non-Diabetic Adults with Chronic Kidney Disease and Overweight or Obesity.” Nature Medicine. 2025. Read article
